Acadia Pharmaceuticals (ACAD) risk factors, FY2025 10-K

Risks Related to Our Products and Product Candidates

1. 01Our prospects are highly dependent on the successful commercialization of our products. To the extent we cannot establish, maintain or increase sales of our products, our business, financial condition and results of operations may be materially adversely affected and the price of our common stock may decline
2. 02any negative publicity related to our products
3. 03Our products may not gain maximal acceptance among physicians, patients, caregivers and the medical community, thereby limiting our potential to generate revenues
4. 04our ability to obtain and maintain sufficient third-party insurance coverage or adequate reimbursement levels
5. 05Our ability to generate product revenues will be diminished if coverage for our products from commercial or government payors is not provided, is decreased or if patients have unacceptably high out-of-pocket requirements36% rewritten
6. 06Our products are subject to ongoing regulatory requirements that could cause us significant expense and delay or limit our ability to generate sales revenues26% rewritten
7. 07seizure or detention, or refusal to permit the import or export of products
8. 08We rely on a limited network of third-party distributors and pharmacies to market and sell our products. If this approach ceases to be effective, commercialization of our products may be adversely affected, and our products may not be profitable
9. 09Drug development is a long, expensive and unpredictable process with a high risk of failure, and there is no guarantee that our products or product candidates will be successful in ongoing or future clinical trials or obtain regulatory approval
10. 10the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities42% rewritten
11. 11With the completion of the Pediatric Phase 2 Trial, we believe we now have completed the FDA’s requirements to qualify for a pediatric exclusivity for pimavanserin. However, there is no assurance that the FDA will confirm that such requirements have been met and that the pediatric exclusivity will be granted87% rewritten
12. 12Any of the above events could prevent us from achieving market approval of trofinetide and could substantially increase the costs of commercializing trofinetideNew
13. 13Expanded access or compassionate use programs could subject us to additional risks32% rewritten
14. 14Delays, suspensions, variations and terminations in our clinical trials for our product candidates could result in increased costs to us and delay our ability to generate product revenues73% rewritten
15. 15insufficient supply or deficient quality of product candidates or other materials necessary for the conduct of our clinical trials

Risks Related to Our Business

1. 16If we fail to develop, acquire or in-license other product candidates or products, our business and prospects would be limited. Even if we obtain rights to other product candidates or products, we will incur a variety of costs and may never realize the anticipated benefits
2. 17We may require additional financing in the future to fund our operations. If we cannot raise additional financing in the future, we may be unable to fund our business plan and our future research, development, commercial and manufacturing efforts
3. 18the costs associated with litigation, including the costs incurred in defending against any product liability claims that may be brought against us related to our products
4. 19We expect that our results of operations will fluctuate, which may make it difficult to predict our future performance from period to period
5. 20We believe that comparisons from period to period of our financial results are not necessarily meaningful and should not be relied upon as indications of our future performance55% rewritten
6. 21Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations71% rewritten
7. 22Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited
8. 23Tax authorities could reallocate our taxable income among our subsidiaries, which could increase our overall tax liability
9. 24Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations
10. 25International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospectsNew
11. 26We or the third parties upon whom we depend may be adversely affected by catastrophic events, such as earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster72% rewritten
12. 27Our business involves the use of hazardous materials, and we and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business
13. 28Our management has broad discretion over the use of our cash and we may not use our cash effectively, which could adversely affect our results of operations

Risks Related to Our Relationships with Third Parties

1. 29We depend on collaborations with third parties to develop certain of our product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates
2. 30cannot obtain the necessary regulatory approvals
3. 31Our collaborations may be subject to conflicts or disputes, which could have a material adverse effect on our business, results of operations and financial condition
4. 32Conflicts arising with our collaborators could impair the progress of our product candidates, harm our reputation, result in a loss of revenues, reduce our cash position, and cause a decline in our stock price
5. 33the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners
6. 34We rely on third parties to conduct our clinical trials and perform data collection and analysis, which may result in costs and delays that prevent us from successfully commercializing product candidates, if approved
7. 35the quality or accuracy of the data obtained by these third parties is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons
8. 36We have no manufacturing facilities and only limited experience as an organization in the manufacturing of drugs or in designing drug-manufacturing processes. We have contracted with third-party manufacturers to produce, in collaboration with us, our products and product candidates56% rewritten
9. 37We may not be able to continue or fully exploit our collaborations with outside scientific and clinical advisors, which could impair the progress of our clinical trials and our research and development efforts

Risks Related to Our Intellectual Property

1. 38Our ability to compete may decline if we do not adequately protect our proprietary rights
2. 39technology that we may in-license may become important to some aspects of our business; however, we generally would not control the patent prosecution, maintenance or enforcement of any such in-licensed technology
3. 40Confidentiality agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete
4. 41A dispute concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be time-consuming and costly, and an unfavorable outcome could harm our business
5. 42As a result, we could be prevented from commercializing current or future products
6. 43The patent applications of pharmaceutical and biotechnology companies involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position

Risks Related to Government Regulation and Our Industry

1. 44Healthcare reform measures may negatively impact our ability to sell NUPLAZID, DAYBUE or our product candidates, if approved, profitably
2. 45In both the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the healthcare system in ways that could impact our ability to sell our products, as described in greater detail in the Government Regulation section of this report80% rewritten
3. 46The implementation of cost-containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products45% rewritten
4. 47We could face liability if a regulatory authority determines that we are promoting our products for any “off-label” uses
5. 48Changes at the FDA and other government agencies could delay or prevent new products from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business
6. 49We are subject to stringent regulation in connection with the marketing of our products, which could delay the development, approval and commercialization of our products52% rewritten
7. 50If our competitors develop and market products that are more effective than our products, they may reduce or eliminate our commercial opportunity33% rewritten
8. 51commercializing pharmaceutical products
9. 52If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products, or development or commercialization of our product candidates, if approved
10. 53a decline in our stock price
11. 54In the ordinary course of our business, we, or the third parties with whom we work, process proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, and trade secrets89% rewritten
12. 55Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations

Risks Related to Our Common Stock

1. 56Our stock price historically has been, and is likely to remain, highly volatile
2. 57economic and political factors, including but not limited to economic and financial crises, wars, terrorism, and political unrest
3. 58If we or our stockholders sell substantial amounts of our common stock, the market price of our common stock may decline47% rewritten
4. 59If our officers, directors, and largest stockholders choose to act together, they may be able to significantly influence our management and operations, acting in their best interests and not necessarily those of our other stockholders
5. 60Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us more complicated and may make the removal and replacement of our directors and management more difficult
6. 61provide for a board of directors with staggered terms
7. 62Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employeesNew
8. 63We do not intend to pay dividends on our common stock in the foreseeable future; as such, you must rely on stock appreciation for any return on your investment